Hematology

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Serum biochemical fingerprints can stratify chronic lymphocytic leukemia (CLL) outcomes and uncover heterogeneity within molecularly defined low-risk disease.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.

A novel combination therapy enhances the effectiveness of proteasome inhibitors against acute myeloid leukemia (AML), improving survival rates in preclinical models.

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

Nanopore sequencing of chronic lymphocytic leukemia (CLL) may be a particularly good fit in under-resourced areas due to its lower cost and smaller laboratory footprint.

Patients with immunoglobulin M-type monoclonal gammopathy did not experience a survival benefit from targeted therapies, a study found.

Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for transplant or CAR T-cell Therapy.

Patients with essential thrombocythemia live with a risk of developing serious bleeding complications, a new study explains.

A case series suggests using minimal residual disease to trigger anti-CD20 therapy for chronic lymphocytic leukemia (CLL) can add years to some patients’ lives.

Teclistamab shows promising real-world effectiveness and safety in older adults with relapsed/refractory multiple myeloma (R/R MM), matching clinical trial outcomes.

Four autophagy-related variants in CDKN2A and BCL2 may increase susceptibility to chronic lymphocytic leukemia (CLL).

As oncology continues to move more toward precision medicine, tools like EVOFLUx may offer a more personalized roadmap from diagnosis to treatment.

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

Positive topline data from the phase 3 BRUIN CLL-313 showed pirtobrutinib's efficacy in the frontline setting.

Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.

Outpatient treatment with axi-cel shows promising response rates for relapsed large B-cell lymphoma, enhancing accessibility in community oncology settings.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need for therapies that offer a sense of normalcy to individuals with polycythemia vera.

The findings could help clinicians individualize infection-prevention strategies in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Outcomes in accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasm (MPN) differ from AML, and AML-based frameworks may not fully capture prognosis in this population.

Patients with severe sickle cell disease experienced significant quality of life improvements after receiving exagamglogene autotemcel gene therapy.